H. Lundbeck A/S increases its share capital by 115,722 shares (0.0590% of outstanding shares) as a result of employee warrant exercise
Valby, Denmark, 21 May 2014 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 578,610, as a consequence of the exercise of employee warrants.
The increase is affected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 17,017 shares at DKK 97; 12,417 shares at DKK 102, 11,460 shares at 115 and 74,828 shares at DKK 121. Proceeds to the company are DKK 13,289,271 (approximately USD 2,439,383). The increase corresponds to approximately 0.0590% of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the time of registration of the capital increase, i.e. inter alia full rights to dividends for the financial year 2014. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority. Lundbeck's current share capital amounts to DKK 981,315,140 and will after the capital increase be DKK 981,893,750. The capital increase is expected to be finalized shortly.
Lundbeck contacts
| Investors: | Media: |
| Palle Holm Olesen | Mads Kronborg |
| Vice President, Investor Relations | Director, Media Relations |
| palo@lundbeck.com | mavk@lundbeck.com |
| +45 36 43 24 26 | +45 36 43 30 00 |
| Jens Høyer | |
| Specialist, Investor Relations | |
| jshr@lundbeck.com | |
| +45 36 43 33 86 | |
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our development and distribution of pioneering treatments continues to make a difference to people living with brain diseases. Our key areas of focus are alcohol dependence, Alzheimer’s disease, depression/ anxiety, epilepsy, Huntington’s disease, Parkinson’s disease, schizophrenia and stroke.
Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales, and are committed to improving the quality of life of people living with brain diseases. Our pipeline consists of several late-stage development programs and our products are available in more 100 countries. We have research centers in China, Denmark and the United States, and production facilities in China, Denmark, France, Italy and Mexico. Lundbeck generated revenue of DKK 15.3 billion in 2013 (EUR 2.0 billion; USD 2.7 billion).